Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644941 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
A Phase 3 study, sponsored by Humacyte.
- Completed
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
NCT02644941 is a Phase 3 study that has completed, run by Humacyte. The registered enrollment target is 355 participants.
The verdict
NCT02644941, a Phase 3 study, has completed, sponsored by Humacyte.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
Interventions
- BIOLOGICAL Human Acellular Vessel (HAV)
- DEVICE ePTFE graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2016-05-24 |
| Est. Completion | 2023-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02644941
The ClinicalTrials.gov registry entry for NCT02644941 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Humacyte, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Human Acellular Vessel (HAV) is the first listed.
NCT02644941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02644941 about?
NCT02644941 is a clinical study titled "Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis". The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
What is the current status of trial NCT02644941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2016-05-24. Estimated completion is 2023-09.
What interventions are being tested in trial NCT02644941?
The interventions under investigation include: Human Acellular Vessel (HAV) (BIOLOGICAL), ePTFE graft (DEVICE).
Who is sponsoring clinical trial NCT02644941?
This trial is sponsored by Humacyte, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.